# 2025年12月31日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 癫痫研究中单项整体评分量表与多项量表的比较：范围综述与荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467957)
**期刊：** Epilepsia
**PMID：** 41467957
**DOI：** 10.1002/epi.70070

### 第一部分 原文与翻译

**英文原标题：** Are single-item global rating scales the same, better, or worse than multi-item scales in epilepsy: A scoping review and meta-analysis.

> **英文摘要：**
> OBJECTIVE: To examine the performance of single-item global ratings (SIGRs) and multi-item scales (MISs) in epilepsy research, and assess the influence of diverse constructs, study designs, and statistical methods.
> 
> METHODS: Systematic scoping review following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) and Joanna Briggs Institute guidelines. MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Register of Controlled Trials were searched from 1980 onward. English-language articles including ≥30 persons with epilepsy and using at least one SIGR and one MIS were analyzed. Citation screening at all levels was done independently by two reviewers; data extraction was standardized. We analyzed individual measurements of effect magnitude for SIGRs and MISs. For meta-analyses, correlation-related metrics were transformed to Pearson r and Fisher z transformed, and effect-size metrics were converted to Cohen's d with Hedges g correction. Multilevel meta-analyses were used to account for data heterogeneity and clustering of effect sizes within studies, and to assess the influence of predefined moderators. Publication bias was assessed with standard methods.
> 
> RESULTS: A total of 18 267 citations were identified, and 58 studies were included. Effect magnitude was medium to large across measurements, and it was slightly larger for MISs than for SIGRs, both for correlations and effect sizes (difference = .04, p < .001). Overall, SIGRs and MISs were comparable, and statistically significant differences did not cross effect thresholds (from small to medium or medium to large). Correlations and effect sizes for SIGRs and MISs were lowest in studies involving children and when assessing change; and for SIGRs when Global Clinical Impression (GCI) formats were used.
> 
> SIGNIFICANCE: SIGRs are likely comparable to MISs across multiple study and statistical contexts. However, in certain clinical scenarios, MISs will outperform SIGRs and vice versa. Researchers should carefully consider whether SIGRs, MISs, or a combination is most appropriate to answer the research question.

> **中文摘要：**
> 目的：评估单项整体评分（SIGRs）与多项量表（MISs）在癫痫研究中的表现，并考察不同构念、研究设计及统计方法的影响。
> 
> 方法：本研究依据系统综述与荟萃分析报告规范（PRISMA）以及Joanna Briggs研究所指南进行系统性范围综述。从1980年起检索MEDLINE、Embase、PsycINFO、CINAHL及Cochrane临床试验注册库。纳入标准为英文文献，研究对象为≥30例癫痫患者，且至少使用一种SIGR与一种MIS。所有引文筛选由两名评审者独立完成，数据提取流程标准化。分析了SIGRs和MISs的效应量度指标。荟萃分析中，将相关性指标转换为皮尔逊r并进行Fisher z变换，效应量指标转换为Cohen's d并经Hedges g校正。采用多层次荟萃分析处理研究间异质性及效应量聚类，并评估预定义调节因素的影响。出版偏倚采用常规方法评估。
> 
> 结果：共检索到18,267条文献，最终纳入58项研究。总体效应幅度为中至大水平，MISs的效应略高于SIGRs，无论在相关性还是效应量方面（差值 = 0.04，p < 0.001）。总体而言，SIGRs与MISs表现相当，统计学显著差异未跨越效应量级阈值（从小到中或从中到大）。SIGRs与MISs的相关性与效应量在儿童研究及变化评估中最低；使用全球临床印象（GCI）格式的SIGRs亦表现较低。
> 
> 结论：SIGRs在多种研究与统计情境下的表现与MISs大体相当。然而，在特定临床场景中，MISs可能优于SIGRs，反之亦然。研究者应根据研究问题谨慎选择使用SIGRs、MISs或二者结合。

### 第二部分 AI 大师评价

该研究系统性评估了单项整体评分与多项量表在癫痫研究中的比较价值，采用PRISMA标准进行范围综述及多层次荟萃分析。结果显示，两种量表的测量效应总体相近，除特定情境（如儿童研究、变化检测）外差异有限。研究创新之处在于首次量化比较两类评分工具在不同统计框架下的表现。然而，由于纳入研究多样性较高，其结论仍需更精细化验证以指导未来临床指标选择。

---

## 2. 预测免疫性脑炎所致新发难治性癫痫持续状态后癫痫发生：DAME评分。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467927)
**期刊：** Epilepsia
**PMID：** 41467927
**DOI：** 10.1002/epi.70081

### 第一部分 原文与翻译

**英文原标题：** Predicting epilepsy after new onset refractory status epilepticus due to autoimmune encephalitis: The DAME score.

> **英文摘要：**
> OBJECTIVE: This study aimed to identify risk factors and develop a predictive scoring system for autoimmune-associated epilepsy in subjects with autoimmune encephalitis presenting with new onset refractory status epilepticus (NORSE).
> 
> METHODS: This retrospective, multicenter, cohort study included subjects who presented with NORSE at the onset of autoimmune encephalitis and had at least 24 months of follow-up after immunotherapy. The outcome was the development of autoimmune-associated epilepsy, defined as persistent seizures despite adequate immunotherapy and absence of active inflammation. Factors independently associated with the outcome were identified through a backward stepwise selection. Adjusted regression coefficients of each independent predictor were transformed to produce a points-based risk-scoring system.
> 
> RESULTS: Seventy participants were included (median age = 24.2 years, 38.6% male). During a median follow-up of 53 months, 54.3% of subjects developed autoimmune-associated epilepsy. Status epilepticus duration ≥ 10 days (odds ratio [OR] = 31.14, 95% confidence interval [CI] = 2.12-456.87, p = .012), positivity for antibodies against surface antigens (OR = .12, 95% CI = .02-.85, p = .034), bitemporal magnetic resonance imaging (MRI) abnormalities suggestive of autoimmune encephalitis during acute stage (OR = 49.80, 95% CI = 2.95-841.77, p = .007), and interictal epileptiform discharges during electroencephalographic (EEG) follow-up (OR = 71.32, 95% CI = 6.48-785.32, p < .001) were independently associated with the study outcome. The duration-antibodies-MRI-EEG (DAME) score was developed as an integer-based scoring system predictive of autoimmune-associated epilepsy. With an optimal cutoff of ≥3 points, it yielded a sensitivity of 86.8%, a specificity of 87.5%, and an overall accuracy of 87.1%.
> 
> SIGNIFICANCE: The DAME score could serve as a user-friendly score to predict the risk of autoimmune-associated epilepsy in patients with NORSE due to autoimmune encephalitis.

> **中文摘要：**
> 研究目的：本研究旨在识别免疫性脑炎伴发新发难治性癫痫持续状态（NORSE）患者中，与免疫相关癫痫发生相关的危险因素，并建立预测评分系统。
> 
> 研究方法：这是一项回顾性、多中心队列研究，纳入在免疫性脑炎发作时出现NORSE并且在免疫治疗后随访至少24个月的患者。研究结局为免疫相关癫痫的发生，定义为在充分免疫治疗后仍有持续性癫痫发作且无活动性炎症存在。采用反向逐步回归法筛选独立相关因素，并将各自的回归系数转换为基于积分的风险评分系统。
> 
> 研究结果：共纳入70例参与者（中位年龄24.2岁，男性占38.6%）。在中位53个月的随访期间，54.3%的受试者发展为免疫相关癫痫。癫痫持续状态持续时间≥10天（比值比[OR]=31.14，95%置信区间[CI]=2.12–456.87，p=0.012）、表面抗原抗体阳性（OR=0.12，95% CI=0.02–0.85，p=0.034）、急性期双侧颞叶MRI异常提示免疫性脑炎（OR=49.80，95% CI=2.95–841.77，p=0.007）以及随访EEG中出现发作间期癫痫样放电（OR=71.32，95% CI=6.48–785.32，p<0.001）均与研究结局独立相关。基于此，研究提出了由持续时间（Duration）、抗体（Antibodies）、MRI及EEG四项构成的DAME评分，这一整数型评分系统可预测免疫相关癫痫的风险。以≥3分为最优界值时，灵敏度为86.8%，特异度为87.5%，总体准确率为87.1%。
> 
> 研究意义：DAME评分提供了一种简便实用的工具，可用于预测免疫性脑炎所致NORSE患者发展为免疫相关癫痫的风险。

### 第二部分 AI 大师评价

该研究针对免疫性脑炎导致的新发难治性癫痫持续状态患者，系统挖掘了癫痫慢性化的关键预测因素，开发了可量化的DAME评分模型。研究设计为多中心回顾性队列，具有较强的临床代表性。结果显示EEG、MRI及病程等指标在预测癫痫发生中独立显著，模型性能优良，便于临床应用。其不足在于样本量有限且需前瞻性验证，但总体为免疫相关癫痫风险评估提供了新的量化工具。

---

## 3. 特发性全身性癫痫患者的癫痫持续状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41467780)
**期刊：** Epilepsia
**PMID：** 41467780
**DOI：** 10.1002/epi.70066

### 第一部分 原文与翻译

**英文原标题：** Status epilepticus in patients with idiopathic generalized epilepsy.

> **英文摘要：**
> OBJECTIVE: To estimate the incidence and determine the consequences of status epilepticus (SE) associated with idiopathic generalized epilepsy (IGE) in adults.
> 
> METHODS: Based on International Classification of Diseases, Tenth Revision (ICD-10) codes we extracted patients with IGE in the period from January 1, 2005 to December 31, 2018, and divided them into two groups: patients with and without a hospitalization with SE before the end of the study. Each patient was matched with 10 normal population controls from the Danish National Patient Register based on age, sex, and geography. Survival, drug resistance, medical history, and surrogate markers for social status were compared.
> 
> RESULTS: We identified 6295 IGE patients and 62 950 normal population controls with slight female preponderance (3338 female; 55.5%). At least one admission with SE was documented for 4.5% (n = 283 patients), of which 57.2% (n = 162) had two or more admissions with SE. The comparison of patients with and without SE before first-time admission for SE showed higher age, surrogate markers for lower social status (affiliation with the labour market, household income, marital status), indicators of more severe IGE (number of antiseizure medications tried, prescription patterns suggestive for drug resistance), and higher psychiatric comorbidity in patients with SE than without. It is important to note that an episode of SE only transiently and slightly affected markers for social status. All-cause mortality was increased in IGE patients with SE (17.7%) as compared to 6.2% in age-matched population controls.
> 
> SIGNIFICANCE: SE in IGE has a high rate of occurrence and is associated with drug-resistant IGE, poor social status, and psychiatric comorbidity already before the first episode of SE. Although the social impact of SE in the short term remains limited, all-cause mortality after SE is increased.

> **中文摘要：**
> 目的：估计成人特发性全身性癫痫（IGE）相关的癫痫持续状态（SE）的发病率，并确定其后果。
> 
> 方法：基于《国际疾病分类》第十版（ICD-10）编码，我们提取了2005年1月1日至2018年12月31日期间的IGE患者，并将其分为两组：研究结束前有SE住院史者和无SE住院史者。每位患者按年龄、性别和地理位置，从丹麦国家患者登记系统中匹配10名普通人群对照。比较生存情况、药物耐受性、病史及社会地位的替代指标。
> 
> 结果：共纳入6295名IGE患者和62,950名普通人群对照，女性略占优势（3338名女性，占55.5%）。其中，4.5%的患者（n=283）至少有一次SE住院记录，其中57.2%（n=162）有两次或以上的SE住院。将首次SE入院前有无SE病史的患者进行比较发现，有SE的患者年龄较大，社会地位的替代指标较低（如劳动市场参与、家庭收入、婚姻状况），且表现出更严重的IGE特征（尝试的抗癫痫药物数量更多、处方模式提示药物耐药），以及更高的精神共病率。需要注意的是，一次SE事件仅对社会地位指标产生短暂且轻微的影响。与按年龄匹配的普通人群对照（6.2%）相比，具有SE的IGE患者的全因死亡率更高（17.7%）。
> 
> 意义：IGE中的SE发生率较高，且在首次SE发作前即已与药物难治性IGE、较差的社会地位及精神共病有关。尽管SE在短期内对社会功能的影响有限，但SE之后的全因死亡率升高。

### 第二部分 AI 大师评价

该研究利用丹麦国家患者登记系统的大样本数据，系统评估了特发性全身性癫痫患者中癫痫持续状态的发生率及相关影响。结果显示，IGE患者中约4.5%会经历SE，且与药物难治性癫痫、较差的社会地位和精神共病密切相关。研究创新地揭示了SE在发作前后社会功能受限及死亡风险增加的关系。局限性在于其基于登记资料，可能存在诊断及社会指标测量误差，但结果对于临床风险分层及长期管理具有重要参考价值。

---

## 4. MONEAD研究中癫痫女性妊娠期及产后早期的抗癫痫药物给药策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461064)
**期刊：** Neurology
**PMID：** 41461064
**DOI：** 10.1212/WNL.0000000000214483

### 第一部分 原文与翻译

**英文原标题：** Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD.

> **英文摘要：**
> BACKGROUND AND OBJECTIVES: Antiseizure medications (ASMs) undergo marked pharmacokinetic alterations during pregnancy and postpartum. Suboptimal ASM management can lead to adverse maternal and child outcomes. However, there is scant literature to guide how to adjust ASM dosing. This study analyzed how ASMs were dosed in a large observational cohort study of pregnant women with epilepsy (PWWE) who had favorable seizure outcomes.
> 
> METHODS: Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) was a prospective, observational cohort study that enrolled PWWE 2012-2016 across 20 US epilepsy centers. Inclusion criteria were PWWE, ages 14-45 years, and <20 weeks' gestational age. Seizures and ASM type(s) and doses were documented in a daily diary. Our analysis included ASM doses in pregnancy through early postpartum (6 weeks post-delivery). For each ASM, we analyzed percent participants who underwent ≥1 dose change in pregnancy and postpartum, time of first dose change after enrollment, time to subsequent changes, amount of each dose adjustment, and percent of conception dose at delivery and 6-week postpartum.
> 
> RESULTS: A total of 299 participants (median 31 [range 17-46] years) were eligible for analysis. Median enrollment was 14-weeks gestation. Dose increases were made in 246/363 (67.8%) of ASMs during pregnancy beginning median 32 days post-enrollment; dose decreases were made within 6 weeks post-delivery for 171/357 (47.9%) of ASMs beginning median 3 days postpartum. For lamotrigine, 128/146 (87.7%) participants had doses increased, by 100 mg/d (median), reaching 191% of conception dose (mean) by delivery. Postpartum, 103/146 (70.5%) had dose tapers, by 100 mg/d (median), to 116% of conception dose (mean) by 6 weeks. For levetiracetam, 70/125 (56.0%) participants had doses increased, by 500 mg/d (median), reaching 177% of conception dose (mean) by delivery. Postpartum, 43/125 (34.4%) had dose tapers, by 500 mg/d (median), to 136% of conception dose (mean) by 6 weeks. For other ASMs, 10/14 had doses increased in pregnancy and 8/14 were tapered early postpartum.
> 
> DISCUSSION: Previous MONEAD analyses showed no difference in seizure control between pregnant and nonpregnant women with epilepsy. We detail how ASMs were managed in pregnancy and early postpartum to achieve this favorable outcome. These findings can be useful for the management of PWWE. Limitations of this study include limited data in the first trimester, enrollment from epilepsy centers, and limited number of participants on a wider variety of ASMs.
> 
> TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT01730170. Study Details | Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) | ClinicalTrials.gov. First submitted: November 9, 2012. First patient enrolled: December 19, 2012.

> **中文摘要：**
> 背景与研究目的：抗癫痫药物（ASMs）在妊娠期和产后会经历显著的药代动力学变化。不理想的ASM管理可能导致母体和儿童的不良结局。然而，目前缺乏指导如何调整ASM剂量的文献。本研究分析了一项大型观察性队列研究中癫痫孕妇（PWWE）在获得良好癫痫控制情况下的ASM给药情况。
> 
> 方法：母体结局与抗癫痫药物神经发育效应（MONEAD）研究是一项前瞻性观察性队列研究，于2012年至2016年在美国20个癫痫中心招募PWWE。纳入标准为：14至45岁女性，妊娠小于20周。癫痫发作情况及ASM种类和剂量均通过日记每日记录。我们的分析涵盖了妊娠期至产后早期（产后6周）内的ASM剂量。针对每种ASM，分析了妊娠期和产后至少经历一次剂量调整的参与者比例、首次调整时间、后续调整时间、每次调整的剂量幅度，以及分娩和产后6周时相对于受孕剂量的比例。
> 
> 结果：共有299名参与者（中位年龄31岁，范围17–46岁）纳入分析。中位入组孕周为14周。妊娠期有246/363（67.8%）个ASM增加了剂量，入组后中位32天开始调整；产后6周内有171/357（47.9%）个ASM减量，产后中位3天开始调整。拉莫三嗪方面，128/146（87.7%）名参与者增加剂量，中位每日增加100 mg，至分娩时平均达到受孕剂量的191%。产后，103/146（70.5%）名参与者进行剂量递减，中位每日减100 mg，于产后6周降至平均受孕剂量的116%。左乙拉西坦方面，70/125（56.0%）名参与者增加剂量，中位每日增加500 mg，分娩时平均达受孕剂量的177%；产后，43/125（34.4%）名参与者递减剂量，中位每日减500 mg，产后6周为平均受孕剂量的136%。其他ASMs中，妊娠期有10/14增加剂量，产后早期8/14减量。
> 
> 讨论：既往MONEAD分析显示，妊娠期与非妊娠期癫痫女性的发作控制并无差异。本研究详细说明了ASMs在妊娠及产后早期的管理策略以实现这一良好结局。这些结果可为癫痫孕妇的临床管理提供参考。研究局限包括：第一孕期数据有限、样本来自癫痫中心，以及使用其他类型ASMs的受试者数量较少。
> 
> 试验注册信息：ClinicalTrials.gov编号NCT01730170。研究详情 | 母体结局与抗癫痫药物神经发育效应（MONEAD）| ClinicalTrials.gov。首次提交：2012年11月9日。首位受试者入组：2012年12月19日。

### 第二部分 AI 大师评价

本研究基于MONEAD前瞻性队列系统分析了癫痫女性在妊娠期及产后早期抗癫痫药物的动态调整特征。结果揭示拉莫三嗪和左乙拉西坦在妊娠期普遍需剂量增加，而产后6周内多有减量。研究为临床制定个体化给药策略提供了关键数据支撑。其创新在于首次系统量化不同阶段的剂量变化过程，但样本构成及早孕期数据受限，仍需进一步验证。

---

## 5. 鼻内给药塞来特拉西坦在阅读性癫痫患者中的应用：首次用于预防反射性癫痫发作的人体研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41459805)
**期刊：** Annals of neurology
**PMID：** 41459805
**DOI：** 10.1002/ana.78128

### 第一部分 原文与翻译

**英文原标题：** Intranasal Seletracetam in a Patient with Reading Epilepsy: First-in-Human Use to Prevent Reflex Seizures.

> **英文摘要：**
> We report the first human use of intranasal seletracetam (SEL) to prevent reflex seizures. A patient with epilepsy with reading-induced seizures on levetiracetam (3,000 mg/day) continued to experience reading-induced focal seizures with preserved consciousness. Detectable in serum within 2 minutes of intranasal administration, 30 mg seletracetam delayed seizure onset from 1:56 (placebo) to 4:17 minutes post-stimulus onset. A second 30 mg dose fully prevented seizures during 25 minutes of reading. Electroencephalogram (EEG) spike-frequency declined dose-dependently (3.1/min at placebo to 1.6/min after second dose), with reduced spike-propagation on magnetoencephalography (MEG). Our findings support SEL as a promising non-benzodiazepine acute seizure prevention and provide insight into reflex seizure dynamics. ANN NEUROL 2025.

> **中文摘要：**
> 我们报道了首次在人类中使用鼻内给药的塞来特拉西坦（SEL）以预防反射性癫痫发作。一名接受左乙拉西坦（3,000 mg/天）治疗但仍出现阅读诱发局灶性癫痫发作并保持意识的癫痫患者被纳入研究。鼻内给药后2分钟内即可在血清中检测到药物，30 mg 塞来特拉西坦将发作起始时间由安慰剂条件下的1分56秒延迟至刺激开始后4分17秒。第二次给予30 mg 剂量可在连续25分钟阅读过程中完全防止癫痫发作。脑电图（EEG）尖波频率呈剂量依赖性下降（由安慰剂时的3.1次/分钟降至第二次给药后的1.6次/分钟），并在脑磁图（MEG）上显示尖波传播的减少。我们的研究结果支持塞来特拉西坦作为一种有前景的非苯二氮卓类急性癫痫发作预防药物，并为反射性癫痫发作的动态机制提供了新的见解。

### 第二部分 AI 大师评价

该研究首次在人类中探索鼻内给药塞来特拉西坦用于预防阅读诱发性反射性癫痫发作，具有开创性意义。研究采用病例干预方式，通过血药浓度、EEG及MEG指标验证了其快速起效和剂量依赖的神经电生理效应。结果显示，塞来特拉西坦不仅延迟发作时间，还可在足量条件下完全阻止发作，提示其作为急性非苯二氮卓类预防药的潜力。尽管受限于单例观察和短期随访，但该研究为反射性癫痫的即时干预提供了重要线索。

---

速递结束，祝您工作愉快！